Anti-diabetic agents, such as SGLT2 inhibitors (SGLT2i) or GLP1 receptor agonists (GLP1-RA), have been shown to delay the progression of CKD (microalbuminuria, GFR)33–36. Here, SLC5A2 is linked to chronic kidney disease.